Takeda Pharmaceutical Co Ltd v. Qilu Pharmaceutical Hainan Co Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Case Name: Takeda Pharmaceutical Company Limited v. Qilu Pharmaceutical (Hainan) Co., Ltd.
  • Plaintiff: Takeda Pharmaceutical Company Limited (Japan)
  • Defendant: Qilu Pharmaceutical (Hainan) Co., Ltd. (China)
  • Plaintiff's Counsel: Saul Ewing LLP
• Case Identification: 2:26-cv-01633, D.N.J., 02/18/2026
• Venue Allegations: Venue is alleged to be proper based on Defendant's business of developing, manufacturing, marketing, and selling pharmaceutical products throughout the United States, including in the District of New Jersey, and the district being a likely destination for the accused generic drug product.
• Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of Plaintiff's LIVTENCITY® (maribavir) tablets constitutes infringement of six U.S. patents covering compositions and methods of using maribavir.
• Technical Context: The technology relates to maribavir, an antiviral drug used for treating cytomegalovirus (CMV) infections, a significant complication for patients who have received organ or stem cell transplants.
• Key Procedural History: The action arises under the Hatch-Waxman Act, triggered by Defendant's submission of ANDA No. 221142 with a Paragraph IV Certification. This certification asserts that Defendant's proposed generic product does not infringe the patents-in-suit or that the patents are invalid. Plaintiff received a notice letter regarding this certification on January 9, 2026.

Case Timeline

Date	Event
2010-10-28	Priority Date for '632 and '169 Patents
2021-11-19	Priority Date for '989, '907, and '170 Patents
2022-10-12	Priority Date for '940 Patent
2023-06-27	U.S. Patent No. 11,684,632 Issues
2025-02-04	U.S. Patent No. 12,213,989 Issues
2025-05-13	U.S. Patent No. 12,295,940 Issues
2025-10-07	U.S. Patent No. 12,433,907 Issues
2025-10-21	U.S. Patent No. 12,447,169 Issues
2025-10-21	U.S. Patent No. 12,447,170 Issues
2026-01-09	Defendant Purportedly Provides Notice Letter to Plaintiff
2026-02-18	Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,684,632 - "Maribavir Isomers, Compositions, Methods of Making and Methods of Using"

• Patent Identification: U.S. Patent No. 11,684,632, "Maribavir Isomers, Compositions, Methods of Making and Methods of Using," issued June 27, 2023.

The Invention Explained

• Problem Addressed: The patent's background section describes the unexpected discovery that the antiviral drug maribavir can convert into other isomers (molecular variants) inside the body (in vivo) ʼ632 Patent, col. 1:55-61 This isomerization is believed to dilute the drug's effective concentration and reduce its therapeutic efficacy, potentially explaining why a prior Phase 3 clinical trial failed to meet its primary endpoint ʼ632 Patent, col. 2:9-19
• The Patented Solution: The patent claims methods of administering maribavir that mitigate this isomerization problem. The core solution involves specific dosing protocols, such as administering the drug under "fasted conditions" (i.e., without food), which was found to differ from a later, less successful clinical trial that allowed dosing with food ʼ632 Patent, col. 2:42-56 The claims cover methods of treating specific patient populations (e.g., transplant recipients) with a defined dose (400 mg twice daily) under these improved conditions ʼ632 Patent, claims 1, 6, 11
• Technical Importance: This invention provided a potential solution to a major clinical development setback, offering a path to restore the efficacy of a promising antiviral drug for vulnerable transplant patients by controlling dosing protocols.

Key Claims at a Glance

• The complaint asserts infringement of "one or more claims" Compl. ¶33 The patent's independent claims are 1, 6, and 11. Claim 1 is representative:
  • A method for treatment of a herpes viral infection in a patient in need thereof
  • comprising orally administering to said patient the compound 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole, or an isomer of said compound,
  • in an amount of 400 mg twice a day,
  • wherein said patient is a stem cell transplant recipient.
• The complaint does not explicitly reserve the right to assert dependent claims, but this is standard practice.

U.S. Patent No. 12,213,989 - "Use of Maribavir in Treatment Regimens"

• Patent Identification: U.S. Patent No. 12,213,989, "Use of Maribavir in Treatment Regimens," issued February 4, 2025.

The Invention Explained

• Problem Addressed: The patent addresses the challenge of administering maribavir to transplant patients who are also taking other necessary medications ʼ989 Patent, col. 1:19-24 Maribavir is metabolized primarily by the enzyme CYP3A4, and co-administration with drugs that induce this enzyme (such as certain anticonvulsants) can decrease maribavir's plasma concentration and reduce its antiviral effect ʼ989 Patent, col. 6:5-12
• The Patented Solution: The patent provides a specific dosing regimen to counteract this drug-drug interaction. It claims a method of treatment that involves administering a higher dose of maribavir (1200 mg orally twice daily) to transplant patients who are also receiving specific CYP3A4-inducing anticonvulsants like phenytoin or phenobarbital ʼ989 Patent, abstract '989 Patent, claim 1 This dose adjustment is intended to maintain therapeutic levels of maribavir despite the increased metabolism caused by the co-administered drug ʼ989 Patent, col. 7:1-12
• Technical Importance: This invention enables the safe and effective use of maribavir in a subset of patients who would otherwise be at risk for treatment failure due to predictable drug-drug interactions.

Key Claims at a Glance

• The complaint asserts infringement of "one or more claims" Compl. ¶42 Independent claim 1 is representative:
  • A method of treating cytomegalovirus (CMV) infection in a patient suffering therefrom,
  • the method comprising administering maribavir in an amount of 1200 mg orally twice daily,
  • wherein the patient is a transplant recipient concomitantly exposed to or receiving an anticonvulsant selected from phenytoin or phenobarbital,
  • wherein maribavir is administered prior to, concurrently with, or subsequently from the administration of the anticonvulsant.
• The complaint does not explicitly reserve the right to assert dependent claims.

U.S. Patent No. 12,295,940 - "Viral Inhibitors, the Synthesis Thereof, and Intermediates Thereto"

• Patent Identification: U.S. Patent No. 12,295,940, "Viral Inhibitors, the Synthesis Thereof, and Intermediates Thereto," issued May 13, 2025 Compl. ¶6
• Technology Synopsis: The patent addresses the low yield and potential for impurities in prior art methods for synthesizing maribavir ʼ940 Patent, col. 2:53-59 The invention discloses an improved, multi-step synthesis process designed to increase the overall yield to at least 45% and better control the formation of byproducts ʼ940 Patent, col. 8:1-13 '940 Patent, claim 1
• Asserted Claims: The complaint alleges infringement of "one or more claims" Compl. ¶51 The patent includes claims to the method of synthesis and compositions of maribavir containing low levels of specific impurities.
• Accused Features: The infringement allegation is aimed at Defendant's manufacture of its generic maribavir product, suggesting the product itself or the process for making it infringes the '940 patent's claims Compl. ¶51 Compl. ¶53

U.S. Patent No. 12,433,907 - "Use of Maribavir in Treatment Regimens"

• Patent Identification: U.S. Patent No. 12,433,907, "Use of Maribavir in Treatment Regimens," issued October 7, 2025 Compl. ¶7
• Technology Synopsis: This patent, a continuation of the '989 patent, addresses drug-drug interactions between maribavir and CYP3A4-inducing anticonvulsants ʼ907 Patent, col. 6:5-12 It claims methods of treating CMV in transplant patients by administering an increased dose of maribavir (1200 mg orally twice daily) when the patient is also receiving phenytoin or phenobarbital, to ensure therapeutic efficacy is maintained ʼ907 Patent, claim 1
• Asserted Claims: The complaint alleges infringement of "one or more claims" Compl. ¶60 Independent claim 1 is representative.
• Accused Features: The administration of Defendant's ANDA product to transplant patients who are also being treated with specific anticonvulsants, pursuant to the product's expected label instructions Compl. ¶60 Compl. ¶62

U.S. Patent No. 12,447,169 - "Maribavir Isomers, Compositions, Methods of Making and Methods of Using"

• Patent Identification: U.S. Patent No. 12,447,169, "Maribavir Isomers, Compositions, Methods of Making and Methods of Using," issued October 21, 2025 Compl. ¶8
• Technology Synopsis: This patent, a continuation of the '632 patent, addresses the problem of in vivo isomerization of maribavir, which can reduce its efficacy ʼ169 Patent, col. 2:9-19 The invention claims methods for treating CMV in specific transplant patient populations by administering 400 mg of maribavir twice daily, including under fasted conditions to mitigate the isomerization ʼ169 Patent, claims 1, 6, 8
• Asserted Claims: The complaint alleges infringement of "one or more claims" Compl. ¶69 Independent claims 1, 6, and 8 are representative.
• Accused Features: The administration of Defendant's ANDA product to specific transplant patient populations at the claimed dosage, in accordance with the product's expected label Compl. ¶69 Compl. ¶71

U.S. Patent No. 12,447,170 - "Use of Maribavir in Treatment Regimens"

• Patent Identification: U.S. Patent No. 12,447,170, "Use of Maribavir in Treatment Regimens," issued October 21, 2025 Compl. ¶9
• Technology Synopsis: This patent, related to the '989 and '907 patents, addresses drug-drug interactions between maribavir and CYP3A4-inducing anticonvulsants ʼ170 Patent, col. 6:5-12 It claims methods for treating CMV infection in transplant patients who are also receiving an immunosuppressant and an anticonvulsant (phenytoin or phenobarbital), by administering a higher dose of maribavir (1200 mg orally twice daily) to counteract the interaction ʼ170 Patent, claim 1
• Asserted Claims: The complaint alleges infringement of "one or more claims" Compl. ¶78 Independent claim 1 is representative.
• Accused Features: The administration of Defendant's ANDA product to transplant patients who are also receiving specific immunosuppressants and anticonvulsants, per the expected label instructions Compl. ¶78 Compl. ¶80

III. The Accused Instrumentality

• Product Identification: The accused instrumentality is Defendant Qilu's "ANDA Product," identified as 200 mg maribavir tablets for which Qilu seeks FDA approval under ANDA No. 221142 Compl. ¶27
• Functionality and Market Context: The complaint alleges that Qilu's ANDA Product is intended to be a generic version of Takeda's LIVTENCITY® drug product Compl. ¶31 LIVTENCITY® is a CMV pUL97 kinase inhibitor used to treat post-transplant CMV infection/disease in patients who are refractory to other treatments Compl. ¶10 The complaint alleges that the FDA-approved labeling for LIVTENCITY® instructs and encourages oral administration according to methods claimed in the patents-in-suit, and that Qilu's product will be used in the same way Compl. ¶13 The patents-in-suit are listed in the FDA's Orange Book for LIVTENCITY®, providing notice to generic manufacturers Compl. ¶11 The '989 patent's Figure 3 shows data from three different human donors illustrating the variable induction of CYP3A4 mRNA expression when exposed to maribavir, supporting the patent's focus on managing drug-drug interactions '989 Patent, FIG. 3

IV. Analysis of Infringement Allegations

The complaint does not contain or reference a claim chart exhibit and provides only general allegations of infringement. The infringement theory is based on 35 U.S.C. § 271(e)(2)(A), where the submission of an ANDA for a drug claimed in a patent or for a use claimed in a patent is an act of infringement. Plaintiff alleges that Defendant's proposed generic product, if approved, would be administered in a manner that directly infringes the asserted method claims, and that the proposed label for the generic product will induce such infringement (Compl. ¶33; Compl. ¶34; Compl. ¶35; Compl. ¶36). The complaint does not provide sufficient detail for a claim-chart-based analysis.

• Identified Points of Contention:
  • Scope Questions: A central dispute for the method-of-use patents ('632, '989, '907, '169, '170) will be whether the specific instructions and indications in Defendant's proposed (but not provided) drug label will fall within the scope of the asserted claims. This raises questions such as: Does the label instruct or encourage administration of a 400 mg twice-daily dose specifically to "stem cell transplant recipients" (as required by claim 1 of the '632 patent)? Does it instruct a dose increase to 1200 mg twice daily when co-administered with "phenytoin or phenobarbital" (as required by claim 1 of the '989 patent)?
  • Technical Questions: For the '940 patent, which claims methods of synthesis and compositions with specific impurity profiles, a key technical question will be evidentiary: Does Defendant's manufacturing process practice the claimed synthesis steps, and does its final drug product contain the specific impurities (or lack thereof) recited in the '940 patent's composition claims?

V. Key Claim Terms for Construction

For U.S. Patent No. 11,684,632:

• The Term: "fasted conditions"
• Context and Importance: This term is central to several dependent claims and is tied directly to the patent's core discovery: that administering maribavir without food mitigates in vivo isomerization and improves efficacy ʼ632 Patent, col. 2:42-56 The scope of this term will define whether a particular administration infringes claims requiring this condition.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The specification provides a general definition: "the condition of not having consumed food during the period between from at least about 3 to 12 hours prior to the administration of maribavir to at least about 1 to 3 hours after the administration" ʼ632 Patent, col. 6:55-63
  • Evidence for a Narrower Interpretation: The specification also states that "Other narrower 'fasted conditions' are also contemplated" and references a prior clinical trial (the "200 Study") that "provided for a fasted dosing protocol" (ʼ632 Patent, col. 2:42-52; '632 Patent, col. 6:63-65). A party might argue the term should be construed more narrowly in line with the specific protocols of such prior studies.

For U.S. Patent No. 12,213,989:

• The Term: "concomitantly exposed to or receiving"
• Context and Importance: This phrase appears in the independent claims and is critical for defining the circumstances under which the claimed method of dose adjustment applies. The dispute will likely focus on the temporal relationship required between the administration of maribavir and the anticonvulsant.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The claim itself states that maribavir can be administered "prior to, concurrently with, or subsequently from the administration of the anticonvulsant" (ʼ989 Patent, claim 1). This language suggests a broad temporal scope, potentially covering any patient on an established regimen for the specified anticonvulsants.
  • Evidence for a Narrower Interpretation: A party could argue that "concomitantly exposed" requires the metabolic effects of the anticonvulsant to be actively present when maribavir is administered. They may contend it requires more than simply having a prescription for the anticonvulsant, pointing to a need for evidence of physiological interaction at the time of treatment.

VI. Other Allegations

• Indirect Infringement: The complaint alleges induced infringement for all asserted patents. The factual basis is the allegation that the Defendant's FDA-approved labeling for its ANDA product will instruct and encourage physicians, pharmacists, and patients to administer the generic drug in a manner that directly infringes the patented methods Compl. ¶13 Compl. ¶36 Compl. ¶45 The complaint also alleges contributory infringement, stating the ANDA product is especially adapted for an infringing use with no substantial non-infringing use Compl. ¶37 Compl. ¶46
• Willful Infringement: The complaint alleges that Defendant has had "knowledge of the [asserted] patent since at least the date of Qilu's ANDA submission" Compl. ¶38 Compl. ¶47 It further seeks a finding that the case is "exceptional" and an award of attorneys' fees under 35 U.S.C. § 285, which is the typical framework for asserting willful infringement or other litigation misconduct Compl. ¶40 Compl. ¶49

VII. Analyst's Conclusion: Key Questions for the Case

1. A core issue will be one of "induced infringement": As the majority of the asserted patents claim methods of use, the dispute will likely depend on whether the specific language in the Defendant's proposed (and as-yet unprovided) drug label is found by the court to actively instruct or encourage physicians and patients to perform the exact steps of the patented methods, including administration to specific patient populations and at specific dosages under defined conditions.
2. A second key question will be one of "claim construction": The interpretation of terms defining the treatment context, such as "fasted conditions" in the '632 patent family and "concomitantly exposed to or receiving" in the '989 patent family, will be critical. The outcome of these construction disputes will determine the scope of the patented methods and the evidence required to prove infringement.
3. For the '940 patent, a central evidentiary question will be one of "process and composition": The case will require a technical comparison of Defendant's confidential manufacturing process and final drug product against the '940 patent's claims, focusing on whether the synthesis methods are practiced or if the resulting product has the claimed impurity profile.